Test | Klas Therapeutics

Novel therapy for the treatment
of malignant Melanoma

Potential for an effective therapy for malignant melanoma that reduces tumour size with minimal systemic side effects and scarring, at a fraction of the cost of current immune based treatments.

Our mission

We are on a mission to revolutionise the treatment of melonoma skin cancer using our patentable Klas-PDT technology.

Clinicians

Lorem ipsum dolor sit amet consectetur.

Patients

Lorem ipsum dolor sit amet consectetur.

Technology

Lorem ipsum dolor sit amet consectetur.

Our mission

We are on a mission to revolutionise the treatment of melonoma skin cancer using our patentable Klas-PDT technology.

KLAS Therapeutics Team

Clinicians

Lorem ipsum dolor sit amet consectetur.

Patients

Lorem ipsum dolor sit amet consectetur.

Technology

Lorem ipsum dolor sit amet consectetur.

Supported by

8575aa99b7e16f9659b29b863c92b234

s960_UKRI_IUK-Logo_OCT2019 1

Our Science

Learn more about how KLAS-PDT works by watching our short explainer video. Our unique compound allows photodynamic therapy (PDT) to be effective against malignant melanoma for the first time, complimenting the current treatment offerings against this deadly cancer.

Our Science

Learn more about how KLAS-PDT works by watching our short explainer video. Our unique compound allows photodynamic therapy (PDT) to be effective against malignant melanoma for the first time, complimenting the current treatment offerings against this deadly cancer.

News

Jun 11, 2026

New imaging captures KLAS-PDT targeting melanoma cells

New imaging has captured our KLAS-PDT technology targeting melanoma cells, offering valuable insight into how the therapy works. Within minutes of activation, we observed disruption of the mitochondria, the cell's energy-producing organelles, helping to reveal the...

Nov 21, 2024

Klas Therapeutics Shines as Seedcorn’s Northern Ireland regional winner

Following months of sequential success in the Seedcorn competition, we are delighted to share that Klas Therapeutics was the Early Stage Regional Winner for Northern Ireland, a testament to our innovative work in transforming melanoma care through our patented...

Sep 16, 2024

Klas receive prestigious Women TechEU award

We are delighted to announce that Klas Therapeutics and our CEO, Prof. Bridgeen Callan, are among the 40 winners of the Women TechEU award. The program received over 800 applications from a range of deep tech female lead companies from across Europe. This EU funded...

Investment Opportunities

KLAS Therapeutics is actively seeking investors who want to make a real difference in the lives of Melanoma sufferers and to become a part of a dynamic team that seeks to push the boundaries of current medical therapies. immune based treatments.